E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Non-small cell lung cancer |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10029522 |
E.1.2 | Term | Non-small cell lung cancer stage IV |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10029521 |
E.1.2 | Term | Non-small cell lung cancer stage IIIB |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficacy of LGX818 as measured by Overall Response Rate (ORR) determined by investigator assessment. |
|
E.2.2 | Secondary objectives of the trial |
Key secondary:
- To evaluate the efficacy of LGX818 as measured by ORR determined by BIRC.
- To evaluate the treatment effect of LGX818 in terms of Progression-Free Survival (PFS) determined by investigator and BIRC.
Other secondary:
- To evaluate Duration of Response (DOR) and Disease Control Rate (DCR) by investigator and BIRC assessments.
- To evaluate overall survival (OS)
- To determine the safety and tolerability of LGX818
- To characterize the pharmacokinetics of LGX818 in this patient population
- To assess the concordance between the BRAF mutation status obtained using the investigational diagnostic test and the companion diagnostic assay which will be submitted for PMA.
|
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Title: To explore potential biomarkes
date and version: 16.01.2014 - v00
Objective: To explore potential biomarkes
|
|
E.3 | Principal inclusion criteria |
- Male or female patients, age ≥ 18 years
- Presence of BRAF V600E mutation in tumor tissue prior to study treatment, as determined by the specified investigational diagnostic test at a Novartis designated central laboratory
- Histologically or cytologically confirmed diagnosis of Stage IIIB or IV NSCLC
- At least one measurable lesion as defined by RECIST v1.1. A previously irradiated site lesion may only be counted as a target lesion if there is clear sign of progression since the irradiation
- Patients must have progressed during or after at least one previous systemic, anti-cancer treatment for locally advanced or metastatic NSCLC.
•Prior cytotoxic chemotherapy must include a platinum doublet.
•(Neo-)adjuvant cytotoxic chemotherapy counts as one prior line of treatment if relapse occurred within 12 months from the end of the (neo-)adjuvant cytotoxic chemotherapy.
- ECOG/World Health Organization (WHO) performance status 0-2
Other protocol-defined inclusion criteria may apply |
|
E.4 | Principal exclusion criteria |
- Patients with symptomatic CNS metastases (neurologically unstable or required increasing doses of steroids within the 2 weeks prior to study entry)
- History of leptomeningeal metastases (carcinomatous meningitis)
- Prior therapy with a BRAF inhibitor
- Patients who have received thoracic radiotherapy to lung fields ≤ 4 weeks prior to starting the study treatment or patients who have not recovered from radiotherapy-related toxicities. For all other anatomic sites (including radiotherapy to thoracic vertebrae and ribs) radiotherapy ≤ 2 weeks prior to starting the study treatment or who have not recovered from radiotherapy-related toxicities. Palliative radiotherapy for bone lesions ≤ 2 weeks prior to starting study treatment is allowed
- Patients taking non-topical medication known to be a strong inhibitor of CYP3A4.However patients who either discontinue their treatment or switch to another medication at least three days prior to the first administration of LGX818 are eligible.
- Patients who underwent major surgery (e.g., intra-thoracic, intra-abdominal or intra-pelvic) within 4 weeks prior (2 weeks for resection of brain metastases) to starting study drug or who have not recovered from side effects of such procedures. Video-assisted thoracic surgery (VATS) and mediastinoscopy will not be counted as major surgery, and patients can be enrolled in the study ≥ 1 week after the procedure
- Presence or history of a malignant disease other than NSCLC that has been diagnosed and/or required therapy within the past 3 years. Exceptions to this exclusion include the following: completely resected basal cell and squamous cell skin cancers, and completely resected carcinoma in situ of any type
- Impaired cardiovascular function or clinically significant cardiovascular diseases
- Uncontrolled arterial hypertension despite medical treatment
- Patient is receiving unstable or increasing doses of corticosteroids. If patients are on corticosteroids for endocrine deficiencies or tumor-associated symptoms (non-CNS), dose must have been stabilized (or decreasing) for at least 5 days before first dose of study treatment
Other protocol-defined exclusion criteria may apply |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Overall Response Rate (ORR), calculated as the proportion of patients with a confirmed best overall response of Complete Response (CR) or Partial Response (PR) (RECIST version 1.1 criteria) per investigator. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Key secondary:
1. ORR, calculated as the proportion of patients with a confirmed best overall response of Complete Response (CR) or Partial Response (PR) (RECIST version 1.1 criteria) per blinded independent review committee(BIRC).
2. PFS, defined as time from start of treatment to date of first documented disease progression (as assessed by investigator/BIRC per RECIST version 1.1 criteria) or date of death due to any cause whichever occurs first.
Other secondary:
3. Duration of response (DOR), defined as the time from date of first documented CR or PR to date of first documented disease progression or death due to any cause whichever occurs first. Disease control rate (DCR), defined as the proportion of patients with best overall response of CR, PR or SD.
4. Overall survival (OS), defined as time from start of treatment to date of death due to any cause.
5. Safety: Adverse events and serious adverse events, changes in laboratory values, vital signs, ECGs, and assessment of physical, dermatological and ocular examinations graded according to the NCI CTCAE v4.03.
6. Plasma concentration-time profiles of LGX818 (and appropriate individual PK parameters based on population PK modeling in a future pooled analysis). Trough concentrations of LGX818 and plasma 4-beta-hydroxycholesterol to account for the attainment of PK steady-state after auto-induction of CYP3A4.
7. Concordance rate between BRAF mutation status obtained using the investigational diagnostic test and the companion diagnostic assay which will be submitted for PMA |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Key secondary:
1 and 2= 36 months
Other secondary:
3 and 4 = 36 months
5 = Continuous Monitoring until 30 days after EOT
6 = Day 1, Day 22, Day 43, Day 64, Day 85 and Day 106
7 = At the time of molecular pre-screening |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 10 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 30 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Bulgaria |
Canada |
China |
France |
Italy |
Japan |
Netherlands |
Argentina |
Germany |
India |
Lebanon |
Spain |
Thailand |
Israel |
Mexico |
Russian Federation |
Singapore |
Switzerland |
Turkey |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of study is defined as the final overall survival analysis timepoint. Based on the protocol assumptions, this is estimated to occur around 36 months. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |